Lessons learned in TB drug discovery: An industrial chemist's perspective

Future Medicinal Chemistry

Volumn 6, Issue 12, 2014, Pages 1377-1380

  Jiricek, Jan ^a  

^a NOVARTIS INSTITUTE FOR TROPICAL DISEASES   (Singapore)

Author keywords

Lead optimization; Lipophilicity; Mycobacterium tuberculosis; Phenotypic screening

Indexed keywords

BEDAQUILINE; DELAMANID; ISONIAZID; RIFAMPICIN; TUBERCULOSTATIC AGENT;

BACTERIAL MEMBRANE; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BIOSAFETY; DRUG DESIGN; DRUG EFFICACY; DRUG RESEARCH; EDITORIAL; HIGH THROUGHPUT SCREENING; INDUSTRIAL CHEMIST; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NAMED GROUPS BY OCCUPATION; PHENOTYPE; RESOURCE ALLOCATION; DRUG DEVELOPMENT; DRUG EFFECTS; HUMAN; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; DRUG DISCOVERY; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84908149207     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/FMC.14.83     Document Type: Editorial

References (20)

1. WHO. Multidrug and Extensively Drug-Resistant TB: 2010 Global Report on Surveillance and Response. WHO, Switzerland (2010).
2. Ma Z, Lienhardt C, McIlleron H, Nunn A. J, Wang, X. Global tuberculosis drug development pipeline: the need and the reality. Lancet 375, 2100-2109 (2010).
3. Koul A, Arnoult E, Lounis N, Guillemont J, Andries K. The challenge of new drug discovery for tuberculosis. Nature 469, 483-490 (2011).
4. Andries K. Discovery and development of bedaquiline: a rocky road. Presented at: 247th ACS National Meeting and Exposition. TX, USA, 16-20 March 2014.
5. Drug Discovery and Development. EMA recommends two new tuberculosis treatments. www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/2013/11/news-detail-001972.jsp&mid=WC0b01ac058004d5c1
6. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6, 29-40 (2007).
7. Pethe K, Sequeira PC, Agarwalla S et al. A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy. Nat. Commun. 1, 57 (2010).
8. Moraski GC, Markley LD, Cramer J et al. Advancement of Imidazo[1,2-a]pyridines with improved pharmacokinetics and nM activity vs. Mycobacterium tuberculosis. Med. Chem. Lett. 4(7), 675-679 (2013).
9. Abrahams KA, Cox JAG, Spivey VL et al. Identification of novel imidazo[1,2-a]pyridine inhibitors targeting M. tuberculosis QcrB. PLoS ONE 7(12), e52951 (2012).
10. Pethe K, Bifani P, Jang J et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat. Med. 19(9), 1157-1160 (2013).
11. Yokokawa F, Wang G, Chan WL et al. Discovery of tetrahydropyrazolopyrimidine carboxamide derivatives as potent and orally active antitubercular agents. ACS Med. Chem. Lett. 4(5), 451-455 (2013).
12. GSK. WO2012143522 A1 20121026 (2012).
13. Kondreddi RR, Jiricek J, Rao SPR et al. Design, synthesis, and biological evaluation of indole-2-carboxamides: a promising class of antituberculosis agents. J. Med. Chem. 56(21), 8849-8859 (2013).
14. Onajole OK, Pieroni M, Tipparaju SK et al . Preliminary structure-activity relationships and biological evaluation of novel antitubercular indolecarboxamide derivatives against drug-susceptible and drug-resistant Mycobacterium tuberculosis strains. J. Med. Chem. 56, 4093-4103 (2013).
15. Varela C, Rittmann D, Singh A et al. MmpL genes are associated with mycolic acid metabolism in mycobacteria and corynebacteria. Chem. Biol. 19(4), 498-506 (2012).
16. Tullius MV, Harmston CA, Owens CP et al. Discovery and characterization of a unique mycobacterial heme acquisition system. Proc. Natl Acad. Sci. USA 108(12), 5051-5056 (2011).
17. Tahlan K, Wilson R, Kastrinsky DB et al. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 56(4), 1797-1809 (2012).
18. Stanley SA, Grant SS, Kawate T et al. Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening. ACS Chem. Biol. 7, 1377-1384 (2012).
19. Goldman RC. Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis? Tuberculosis 93, 569-588 (2013).
20. Wager TT, Kormos BL, Brady JT et al. Improving the odds of success in drug discovery: choosing the best compounds for in vivo toxicology studies. J. Med. Chem. 56, 9771-9779 (2013).